Mostrar el registro sencillo

dc.contributor.authorMartínez-Cué, Carmen 
dc.contributor.authorRueda Revilla, Noemí 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2021-04-16T14:46:17Z
dc.date.available2021-04-16T14:46:17Z
dc.date.issued2020
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10902/21322
dc.description.abstractDown syndrome (DS), the most common cause of intellectual disability of genetic origin, is characterized by alterations in central nervous system morphology and function that appear from early prenatal stages. However, by the fourth decade of life, all individuals with DS develop neuropathology identical to that found in sporadic Alzheimer's disease (AD), including the development of amyloid plaques and neurofibrillary tangles due to hyperphosphorylation of tau protein, loss of neurons and synapses, reduced neurogenesis, enhanced oxidative stress, and mitochondrial dysfunction and neuroinflammation. It has been proposed that DS could be a useful model for studying the etiopathology of AD and to search for therapeutic targets. There is increasing evidence that the neuropathological events associated with AD are interrelated and that many of them not only are implicated in the onset of this pathology but are also a consequence of other alterations. Thus, a feedback mechanism exists between them. In this review, we summarize the signalling pathways implicated in each of the main neuropathological aspects of AD in individuals with and without DS as well as the interrelation of these pathways.es_ES
dc.description.sponsorshipThis research was funded by the Institute of Research Valdecilla (IDIVAL), grant number: NVAL 19/23, approval date: 1 january 2020es_ES
dc.format.extent38 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInt J Mol Sci . 2020 Sep 20;21(18):6906es_ES
dc.subject.otherAlzheimer’s Diseasees_ES
dc.subject.otherDown Syndromees_ES
dc.subject.otherNeurodegenerationes_ES
dc.subject.otherSignalling Pathwayses_ES
dc.titleSignalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndromees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/ijms21186906es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/ijms21186906
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license.